NO952366L - Dolostatin-analog - Google Patents

Dolostatin-analog

Info

Publication number
NO952366L
NO952366L NO952366A NO952366A NO952366L NO 952366 L NO952366 L NO 952366L NO 952366 A NO952366 A NO 952366A NO 952366 A NO952366 A NO 952366A NO 952366 L NO952366 L NO 952366L
Authority
NO
Norway
Prior art keywords
hydrogen
alkyl
alkoxy
benzyl
hydroxy
Prior art date
Application number
NO952366A
Other languages
English (en)
Other versions
NO952366D0 (no
Inventor
Andreas Haupt
Bernd Janssen
Kurt Ritter
Dagmar Klinge
Gerhard Keilhauer
Cynthia Romerdahl
Teresa Barlozzari
Xiao-Dong Qian
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO952366L publication Critical patent/NO952366L/no
Publication of NO952366D0 publication Critical patent/NO952366D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Window Of Vehicle (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Nye peptider med formelen \ N-CHX-CO-(A) -NR3-CHB-CHD-CHE-CO-(R7) -(M) ,-Q hvor H1 er alkoksy; alkyl; cykloalkyl; alkylsulfonyl; trifluor- etyl; fluoretyl; difluoretyl; trifluoracetyl; amidino; ureyl; piperidinosulfonyl; aorfolinosulfonyl; benzyloksy- karbonyl; alkoksykarbonyl; aninosulfonyl son kan veie substituert ned alkyl; hydroksy; fenylsulfonyl som kan v«re substituert ned en eller flere substituenter uavhen- gig valgt fra alkyl, -N(CH.,) , nitro, halogen og CF3: eller NR8B9 hvor R8 og R9 hver kan v«e enten hydrogen eller alkyl; R2 er hydrogen; alkyl; cykloalkyl; acyl; benioyl eller ben- zyl BOB kan vcre substituert ned opp til tre substitu- enter uavhengig valgt fra nitro, halogen, CFa, alkyl og alkoksy (fortrinnsvis C. ); eller R1-N-R2 tilsanaen kan vcre en 5- eller e-leddet heterocyklus son kan vcre usubstituert eller substituert ned en eller flere substituenter uavhengig valgt fra fenyl, benzyl, alkyl, H(CH ) , okso, nitro, tienyl, CONH-, COOMe og COOEt; X er hydrogen, alkyl, cykloalkyl, -CH -cykloheskyl eller benzyl; A er valgt fra gruppen bestående av valyl, isoleucyl, leu- cyl, allo-isoleucyl, a-aninoisobutanoyl, 3-tert.-butyl- alanyl, 2-tert.-butylglycyl, 3-cykloheksylal«nyl, 2-etyl- glycyl eller 2-cykloheKsylglycyl-rester; R3 er hydrogen eller alkyl: B er hydrogen eller alkyl, cykloalkyl, -CH,-cykloheksyl eller benzyl; D er hydrogen, hydroksy, acetoksy eller alkoksy; E er hydrogen eller alkyl; eller B og E tilsanmen er -(CH2)3-, -(CH,),-, -CH(CH )CH,CH,-, -CH(CH )CH2-, -C(CH3)2CH2CM2- eller C(CH.,)2CH2-: H7 er -NR -CHG-CHK-CHL-CO-, eller M er valgt fra gruppen bestående av 1-aninopentyl-l-karbon- yl, valyl, 2-tert.-butylglycyl, prolyl, hydroksyprolyl, isoleucyl, leucyl, }-cykloheksylalanyl, fenylalanyl, tetrahydroisokinolyl-2-karbonyl, 3-tiazolylalanyl, 3- tienylalanyl, histidyl, 2-aninoindyl-2-karbonyl, tyrosyl, 3-pyridylalanyl, 3-tert.-butylalanyl, 2-cykloheksylglycyl eller 3-naftylalanyl-rester: eller R1R2N-CHX-CO- og A tilsamnen er R' r u co- eller hvor T er hydrogen eller lavere alkyl; u er hydrogen eller lave- re alkyl; n er l, 2 eller 3; v er oksygen eller svovel; v er hydrogen; Z er hydrogen eller lavere alkyl: eller y og Z tilsamnen kan danne en binding; w er hydrogen, lavere alkyl eller fenyl; a, b og d uavhengig er o eller 1; Q er hydroksy, alkoksy, fenoksy, benzyloksy eller en sub- stituert eller usubstituert aninogruppe; forutsatt at hvor b og d er o, skal Q ikke v«re en hydroy.sy- eller alkoksygruppe; og saltene derav med fysiologisk aksepterbare syrer. De nye substanser har anti-neoplastisk effekt. hvor V er oksygen eller svovel; YA er hydrogen; Z er hydrogen eller lavere alkyl; eller Y1 og Zl tilaaanen kan danne en binding; w1 er hydrogen, alkyl eller fenyl; R4 er hydrogen eller alkyl: C er hydrogen, alkyl, cykloheksyl, CH -cykloheksyl eller benzyl; K er hydrogen, hydroksy, acetoksy eller alkoksy; L er hydrogen eller alkyl; eller R* og C tllsammen er -(CH,) -, -(CH,),-, eller -CH2,-CH(OH)-CH2 -;
NO952366A 1992-12-16 1995-06-15 Dolostatin-analog NO952366D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99130992A 1992-12-16 1992-12-16
PCT/EP1993/003410 WO1994013695A1 (en) 1992-12-16 1993-12-04 Dolostatin analog

Publications (2)

Publication Number Publication Date
NO952366L true NO952366L (no) 1995-06-15
NO952366D0 NO952366D0 (no) 1995-06-15

Family

ID=25537082

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952366A NO952366D0 (no) 1992-12-16 1995-06-15 Dolostatin-analog

Country Status (24)

Country Link
US (1) US5502032A (no)
EP (1) EP0674652B1 (no)
JP (1) JPH08504415A (no)
CN (1) CN1057095C (no)
AT (1) ATE196296T1 (no)
AU (1) AU679479B2 (no)
BR (1) BR1100019A (no)
CA (1) CA2151953A1 (no)
CZ (1) CZ286752B6 (no)
DE (1) DE69329425T2 (no)
ES (1) ES2151921T3 (no)
FI (1) FI952961A0 (no)
HR (1) HRP931504B1 (no)
HU (1) HUT72067A (no)
IL (1) IL107987A (no)
NO (1) NO952366D0 (no)
NZ (1) NZ258882A (no)
PL (1) PL178766B1 (no)
RU (1) RU2132334C1 (no)
SG (1) SG67935A1 (no)
SI (1) SI9300661A (no)
TW (1) TW400335B (no)
WO (1) WO1994013695A1 (no)
ZA (1) ZA939389B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
CA2360305A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company Lactam inhibitors of fxa and method
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
JP2004518688A (ja) 2001-01-30 2004-06-24 ブリストル−マイヤーズ スクイブ カンパニー ファクターXa阻害剤のスルホンアミドラクタムおよびその方法
JP2005509616A (ja) * 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
EP1636220A1 (en) * 2003-05-12 2006-03-22 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
EP1765332A2 (en) * 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
US20060135483A1 (en) * 2004-07-09 2006-06-22 Cheruvallath Zacharia S Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
EP1841749A1 (en) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
CA2614436C (en) * 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2012171020A1 (en) 2011-06-10 2012-12-13 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
CA2935064C (en) 2013-12-27 2023-06-27 Zymeworks Inc. Var2csa-drug conjugates
CN106255513B (zh) 2013-12-27 2022-01-14 酵活有限公司 用于药物偶联物的含磺酰胺连接系统
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds and methods for their use
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3540495A1 (de) * 1985-11-15 1987-05-21 Merck Patent Gmbh Aminosaeurederivate
DE3787403D1 (de) * 1986-05-09 1993-10-21 Pulverer Gerhard Verwendung von spezifischen Monosacchariden zur Herstellung eines Arzneimittels zur Verhinderung von Metastasen maligner Tumore.
JP2714402B2 (ja) * 1988-07-13 1998-02-16 日清製粉株式会社 癌転移抑制剤
DK414389A (da) * 1988-08-24 1990-02-26 Merck & Co Inc Farmaceutisk praeparat indeholdende et aminosyrederivat med renin-inhibitorisk virkning
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5138036A (en) * 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
DK0934950T3 (da) * 1991-08-09 2002-07-29 Teikoku Hormone Mfg Co Ltd Tetrapeptidderivat

Also Published As

Publication number Publication date
IL107987A (en) 1999-10-28
TW400335B (en) 2000-08-01
FI952961A (fi) 1995-06-15
BR1100019A (pt) 2000-07-25
HRP931504B1 (en) 2001-04-30
FI952961A0 (fi) 1995-06-15
CN1095724A (zh) 1994-11-30
AU679479B2 (en) 1997-07-03
SG67935A1 (en) 1999-10-19
IL107987A0 (en) 1994-04-12
WO1994013695A1 (en) 1994-06-23
RU95115135A (ru) 1997-06-10
DE69329425T2 (de) 2001-01-18
SI9300661A (en) 1994-06-30
JPH08504415A (ja) 1996-05-14
CA2151953A1 (en) 1994-06-23
ES2151921T3 (es) 2001-01-16
HUT72067A (en) 1996-03-28
EP0674652B1 (en) 2000-09-13
HRP931504A2 (en) 1997-02-28
PL309353A1 (en) 1995-10-02
ATE196296T1 (de) 2000-09-15
PL178766B1 (pl) 2000-06-30
CZ157595A3 (en) 1996-01-17
CZ286752B6 (en) 2000-06-14
CN1057095C (zh) 2000-10-04
US5502032A (en) 1996-03-26
ZA939389B (en) 1995-06-15
NO952366D0 (no) 1995-06-15
HU9501754D0 (en) 1995-08-28
EP0674652A1 (en) 1995-10-04
NZ258882A (en) 1997-06-24
DE69329425D1 (de) 2000-10-19
RU2132334C1 (ru) 1999-06-27
AU5695994A (en) 1994-07-04

Similar Documents

Publication Publication Date Title
NO952366L (no) Dolostatin-analog
RU2219167C2 (ru) N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств
ATE203534T1 (de) Angiogenesis hemmende pyridazinamine
IS2657A7 (is) Ný samsetning efnis
NO924929L (no) Farmasoeytisk aktive benzoquinazolinforbindelser
TR199801210T2 (xx) 1-(1,2-�ift ikameli piperidinil)-4-(kayna�m�� imidazol)piperidin t�revleri.
CO4990946A1 (es) Antagonistas del receptor de trombina
ATE236164T1 (de) Antiallergische triazolobenzazepinderivate
TR199801218T2 (xx) Takikinin antagonistleri olarak N-asil-2-ikameli-4-(Benzimidazolil-ya da imidazopiridinil-ikameli art�klar)-piperidinler.
DE59202241D1 (de) Neue Pyridylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung.
TR199700769T1 (xx) Tedaviye faydal� olan bisiklik izotio�re t�revleri.
NZ238033A (en) 1-indanone- or 1-tetralone-2'-amidinohydrazone derivatives and pharmaceutical compositions thereof
DE69104475D1 (de) Harnstoffderivate, ihre herstellung und deren enthaltende arzneimittel.
KR950025039A (ko) 신규의 치환된 피리딘 이미다졸 유도체 및 그의 제조방법
IL62380A0 (en) Novel derivatives of thioformamide,their preparation and medical compositions containing the same
GB1428626A (en) Trisubstituted 1,2,4-triazoles
GB1397886A (en) Benzimidazoles and their use as fungicides and bactericides
FI842976A0 (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva aminopyrimidinonderivat.
GB1230953A (no)
DE3586891D1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE59002774D1 (de) Aromatische Ketoverbindungen, ihre Herstellung und Arzneimittel sowie Kosmetika daraus.
RO65263B (ro) Procedeu pentru prepararea unor derivati ai 6-aza-3h-benzodiazepinelor
KR930007910A (ko) N-메톡시페닐에틸-n'-이미다졸릴페닐아미딘 유도체 및 그의 제조방법
JPS5735555A (en) 3-substituted 2-propenenitrile derivative and its preparation
TH28678B (th) อนุพันธ์ของ 1-(1,2-ไดสับสติติวเตทไพเพอริดินิล)-4-สับสติติวเตทไพเพอราซีน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application